CD4 and neoplasm: Surprisingly, quantification of tumor-infiltrating lymphocytes per gram of tumor tissue (Figure 3b) revealed free and conducting treated oxRilac to be equally efficient in attracting CD4+ (Figure 3c) and CD8+ T cells (Figure 3d) to the tumor side with significant differences compared to untreated controls.